Mesalamine and Rash maculo-papular - a phase IV clinical study of FDA data

Summary:

Rash maculo-papular is reported as a side effect among people who take Mesalamine (mesalamine), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Pantoprazole Sodium, and have Neuroendocrine tumor.

The phase IV clinical study analyzes which people have Rash maculo-papular when taking Mesalamine. It is created by eHealthMe based on reports of 27,767 people who have side effects when taking Mesalamine from the FDA, and is updated regularly.

What is Mesalamine?

Mesalamine has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 28,053 Mesalamine users. Check the latest studies of Mesalamine.

What is Rash maculo-papular?

Rash maculo-papular (red area on the skin that is covered with small confluent bumps) is found to be associated with 1,243 drugs and 1,534 conditions by eHealthMe. Check the latest studies of Rash maculo-papular.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

27,767 people reported to have side effects when taking Mesalamine.
Among them, 31 people (0.11%) have Rash maculo-papular.

Could Mesalamine cause Rash maculo-papular?

Among these 31 people:

How long have people been on Mesalamine when they have Rash maculo-papular? *

What is the gender of people who have Rash maculo-papular when taking Mesalamine? *

female: 51.72 %
male: 48.28 %

What is the age of people who have Rash maculo-papular when taking Mesalamine? *

What are other drugs people take besides Mesalamine? *

What are other side effects people have besides Rash maculo-papular? *

Fever: 10 people, 32.26%
Nasopharyngitis (inflammation of the nasopharynx): 8 people, 25.81%
Oropharyngeal Pain: 7 people, 22.58%
Abdominal Pain: 7 people, 22.58%
Nausea (feeling of having an urge to vomit): 7 people, 22.58%
Diarrhea: 7 people, 22.58%
Fatigue (feeling of tiredness): 7 people, 22.58%
Hypophagia (reduced food intake): 6 people, 19.35%
Injection Site Pain: 6 people, 19.35%
Injection Site Mass: 6 people, 19.35%

What are the existing conditions these people have? *

Neuroendocrine Tumor: 6 people, 19.35%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 12.90%
High Blood Pressure: 4 people, 12.90%
Rickets (softening of bones): 3 people, 9.68%
Indigestion: 3 people, 9.68%
Glaucoma (increased fluid pressure in the eye with vision loss): 2 people, 6.45%
Seasonal Allergy (allergic condition due to certain season): 1 person, 3.23%
Osteoporosis (bones weak and more likely to break): 1 person, 3.23%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 3.23%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Mesalamine and have Rash maculo-papular?

- Check whether Rash maculo-papular is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mesalamine:

Mesalamine (28,053 reports)

Browse all side effects of Mesalamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rash maculo-papular:

Rash maculo-papular (1,243 drugs)

Browse all the conditions that are associated with Rash maculo-papular:

Rash maculo-papular (1,534 conditions)

Related publications that referenced our studies

Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .
Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine (the active ingredients of Mesalamine) and Mesalamine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.